KSKimberly Stegmaier

Kimberly Stegmaier

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kimberly Stegmaier has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma

    by Kimberly Stegmaier

    Alveolar rhabdomyosarcoma (aRMS) is a fusion-driven pediatric cancer with poor survival and limited therapeutic options. To uncover novel vulnerabilities, we used complex-Map functional genomic data, identifying CDK8 as a dependency in aRMS. Both CDK8 knockout and pharmacologic inhibition impaired tumor cell growth and induced myogenic differentiation in vitro and in vivo. Compared with genetic loss, CDK8 pharmacologic inhibition induced more dynamic transcriptional changes. With a genome-scale CRISPR–Cas9 drug modifier screen, we determined that the maximal antitumor activity of the CDK8 inhibitor requires the presence of the Mediator kinase module, including CDK8, and transcriptional cooperation with the SAGA complex. We further identified SIX4 as a key transcription factor mediating CDK8 inhibitor–induced transcriptional activation of myogenic differentiation genes and impaired tumor proliferation. These findings suggest a distinct gain-of-function mechanism of the CDK8 inhibitor and establish a strong rationale for CDK8 inhibition as a differentiation-inducing therapeutic strategy in aRMS. Significance:We provide a framework for uncovering therapeutic targets by network-based analysis of functional genomic screens. We identify CDK8 as a druggable target in aRMS and determine that CDK8 inhibition drives myogenic differentiation and impairs tumor progression via a collaborative mechanism involving the Mediator kinase module, SAGA complex, and SIX4.See related commentary by Stevens and Hatley, p. 2210

  • Open Access

    Supplementary Figures S1-S7 from CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma

    by Susu Zhang, Kathleen L. Engel, Assil Fahs, Ara Jo, Clare F. Malone, Kenneth N. Ross, Marissa Just, Brian Guedes, Diyana Granum, Kristianne M. Oristian, et al.

    Figure S1. Genetic loss of CDK8 impairs cell growth. Figure S2. Pharmacologic inhibition of CDK8 triggers slowed cell proliferation, minimal apoptosis and cell cycle effects. Figure S3. CDK8 inhibition activates myogenic differentiation-associated gene targets. Figure S4. CDK8 inhibitors induce a muscle differentiation program without altering PAX3::FOXO1. Figure S5. Interruption of the SAGA complex rescues the effects of CDK8 inhibitors. Figure S6. CDK8 inhibition increases SIX4-driven muscle differentiation. Figure S7. The Mediator kinase module is required for maximal CDK8 inhibitor activity

  • Open Access

    Supplementary Table S1 from CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma

    by Susu Zhang, Kathleen L. Engel, Assil Fahs, Ara Jo, Clare F. Malone, Kenneth N. Ross, Marissa Just, Brian Guedes, Diyana Granum, Kristianne M. Oristian, et al.

    Supplementary Table S1 of gene targets from NGS data

  • Open Access

    Supplementary Data 1 from A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies

    by David S. Shulman, Kieuhoa T. Vo, Frank M. Balis, Holly Lindsay, Bradley D. DeNardo, Andrew E. Place, Susan N. Chi, Junne Kamihara, Allison F. O’NEill, Alanna J. Church, et al.

    Supplemental Tables 1, 2, and 3

  • Pediatric sarcomas: challenges and opportunities

    by Yuan Gao, Kelly M. Bailey, Samuel C. Blackman, John H. Bushweller, Shasha Chong, Kevin DeHond, Jolanta Grembecka, Mark E. Hatley, Cigall Kadoch, Angela N. Koehler, et al.

    Pediatric sarcomas are a heterogeneous group of rare mesodermal malignancies. These cancers, which affect children from infancy through adolescence and young adulthood, are in general challenging to treat with currently available therapies. Biologically, many are characterized by quiet genomes, fusion oncoproteins, immune “cold” microenvironments, and vast epigenetic deregulation that contributes to diverse and complex mechanistic drivers. Multifaceted advancements in research strategies, including high-throughput screening, new model systems, surfaceome profiling, and study of oncogenic fusion condensates have led to new opportunities for understanding the biology of pediatric sarcomas. To continue to make progress for these difficult to treat cancers, it will be critical to continue to improve access to bioinformatic data, approach patient care using innovative clinical trial frameworks, and foster interdisciplinary partnerships among medicinal chemists, scientists, clinicians, advocates, and industry partners.

  • Open Access

    SNHG family lncRNAs promote Ewing sarcoma cell fitness through intronic snoRNA-guided rRNA modifications

    by Marcela Briones-Martin-Del-Campo, Alex G Lee, Truc Dinh, Virginie Marchand, Yuri Motorin, Marta Román, Qiuli Bi, Stanley G Leung, Max A Horlbeck, Leanne C Sayles, et al.

    Over 90% of Ewing sarcomas (EWS) are driven by the EWS–FLI1 fusion oncoprotein. EWS–FLI1 acts as a pioneer transcription factor, altering the expression of hundreds of genes including many long non-coding RNAs (lncRNAs). The role of these lncRNAs in the oncogenesis of EWS is mostly unknown. We developed a CRISPR interference (CRISPRi) strategy to knock down expression of lncRNA loci expressed in EWS and evaluate their effect on proliferation in vitro and tumor growth in vivo. While most lncRNA knockdown had minimal effect on cell proliferation, selective inhibition of SNHG1, SNHG12, and SNHG30 significantly reduced both proliferation of Ewing cells in vitro and the growth of Ewing tumors in vivo. These results were validated by individual knockdown followed by RNA-seq to assess their functional impact. We observed a decrease in post-transcriptional modifications (2′-O-methylation and pseudouridylation) at specific rRNA positions known to be guided by snoRNAs encoded in SNHG1 and SNHG12. Collectively, we demonstrate that expression of SNHG1, SNHG12, and SNHG30 in EWS cells contributes to the maintenance of cancer cell fitness via their role in intron-processed snoRNA genes. Thus, post-transcriptional regulation of rRNA may be a previously underappreciated consequence of EWS–FLI1 expression.

  • Open Access

    CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-Driven Alveolar Rhabdomyosarcoma

    by Susu Zhang, Kathleen L. Engel, Assil Fahs, Ara Jo, Clare F. Malone, Kenneth N. Ross, Marissa Just, Brian Guedes, Diyana Granum, Kristianne M. Oristian, et al.

    Alveolar rhabdomyosarcoma (aRMS) is a fusion-driven pediatric cancer with poor survival and limited therapeutic options. To uncover novel vulnerabilities, we used complex-Map functional genomic data, identifying CDK8 as a dependency in aRMS. Both CDK8 knockout and pharmacologic inhibition impaired tumor cell growth and induced myogenic differentiation in vitro and in vivo. Compared with genetic loss, CDK8 pharmacologic inhibition induced more dynamic transcriptional changes. With a genome-scale CRISPR–Cas9 drug modifier screen, we determined that the maximal antitumor activity of the CDK8 inhibitor requires the presence of the Mediator kinase module, including CDK8, and transcriptional cooperation with the SAGA complex. We further identified SIX4 as a key transcription factor mediating CDK8 inhibitor–induced transcriptional activation of myogenic differentiation genes and impaired tumor proliferation. These findings suggest a distinct gain-of-function mechanism of the CDK8 inhibitor and establish a strong rationale for CDK8 inhibition as a differentiation-inducing therapeutic strategy in aRMS. Significance: We provide a framework for uncovering therapeutic targets by network-based analysis of functional genomic screens. We identify CDK8 as a druggable target in aRMS and determine that CDK8 inhibition drives myogenic differentiation and impairs tumor progression via a collaborative mechanism involving the Mediator kinase module, SAGA complex, and SIX4. See related commentary by Stevens and Hatley, p. 2210


  • Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia

    by Camille Vaganay, Frank Ling, Lois M. Kelly, Juliette Charles, Paul-Arthur Meslin, Hélène Pasquer, Rathana Kim, Marie Passet, Matthieu Duchmann, Léa Pelissier-Menjaud, et al.

    Chemotherapy resistance in acute myeloid leukemia (AML) remains a major clinical challenge. Integration of multiomic profiling and in vivo functional genomics revealed splicing dysregulation as a determinant of chemoresistance in AML. We uncovered a network involving the splicing regulator SRRM1 and the CLK1/4 and PAK1 kinase families as vulnerabilities in chemoresistant AML cells. Both kinase families are hyperactivated in chemoresistant cells, promoting SRRM1 phosphorylation and altering its scaffolding function. We also identified a relapse-associated PAK1 variant, c.1429G>T p.(Ala 477 →Ser), that confers chemotherapy resistance. Combined PAK1 and CLK1/4 inhibition recapitulated the splicing changes induced by SRRM1 loss, preferentially targeting chemoresistant AML and enhancing chemotherapy efficacy in cell lines, primary cells, and mouse models. Last, we pinpointed MAP2K5 as a critical downstream effector because missplicing of exons 17 and 18 of MAP2K5 upon SRRM1 depletion sensitized cells to chemotherapy. Our findings highlight a therapeutic strategy to overcome AML relapse by targeting splicing dysregulation.

  • Open Access

    Data from Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation

    by Emily A. Cmarik, Abhishek Wahi, Sayali S. Chandekar, Solomon K. Otchere, Jennifer E. Sturgis, Silvi Salhotra, Allen T. Basanthakumar, Nehemiah X. Boyd, Giulia DiGiovanni, He Zhu, et al.

    Pediatric cancers are frequently driven by genomic alterations that result in impaired differentiation during development. To identify complex-level dependencies required for differentiation in neuroblastoma, a pediatric cancer of the developing peripheral nervous system, we curated a list of protein complexes using the CORUM database and mined the Dependency Map using gene set enrichment analysis. This analysis identified the noncanonical polycomb repressive complex 1.1 (PRC1.1) complex, which represses transcriptional activity through ubiquitination of histone 2A, lysine 119 (H2AK119Ub), as a selectively enriched dependency in neuroblastoma. Knockout of PRC1.1 subunits reduced neuroblastoma growth by inducing a neuronal differentiation program. Although no known direct inhibitors of PRC1.1 exist, codependency analysis identified that the deubiquitinase USP7 strongly correlated with PRC1.1 dependency. Treatment with XL177A, a small molecule inhibitor of USP7, significantly reduced neuroblastoma growth in both cellular and animal models. Integrated RNA and chromatin immunoprecipitation sequencing showed that both PRC1.1 knockout and USP7 inhibition resulted in highly correlated transcriptional alterations and reduced H2AK119Ub deposition on chromatin, suggesting that USP7 inhibition reduced neuroblastoma growth through a PRC1.1-dependent mechanism. Mechanistically, global proteomics and ubiquitinomics revealed that USP7 inhibition disrupted noncanonical PRC1 complex assembly, resulting in the destabilization of PRC1.1 and subsequent proteolysis. Our findings expand our understanding of the chromatin complexes required to maintain a dedifferentiated state in neuroblastoma and suggest the therapeutic potential for USP7 inhibitors in the treatment of this disease.Implications:Our study reveals the potential for utilizing USP7 inhibitors to target epigenetic repression of differentiation programs in neuroblastoma by reducing PRC1 activity.

  • Open Access

    Supplementary Figure S6 from Inhibition of USP7 Destabilizes the Noncanonical PRC1.1 Complex and Induces Neuroblastoma Differentiation

    by Emily A. Cmarik, Abhishek Wahi, Sayali S. Chandekar, Solomon K. Otchere, Jennifer E. Sturgis, Silvi Salhotra, Allen T. Basanthakumar, Nehemiah X. Boyd, Giulia DiGiovanni, He Zhu, et al.

    Figure S6 shows consequences of PRC1 function and activity with USP7 inhibition.